A Nested Case-Control Study of Luteinizing Hormone Variants and Risk of Breast Cancer
Abstract
An immunological variant of luteinizing hormone (LH) dependent on two pint mutations in the gene of the LHBeta-submit has increased in vitro bioactivity and is detectable in serum with immunofluorometric assays (lFMA). The variant occurs with a frequency of 5--2% in the general population. The altered bioactivity and kinetics of the LH variant are accompanied by changes in LH action and by increased stimulation of the ovarian stromal cells and may be followed by increased production of ovarian testosterone and androstenedione and their estrogen metabolites estradiol and estrone. The study takes advantage of an on-going prospective cohort study of hormones and breast cancer. Serum samples from cohort subjects are being assayed for testosterone, androstenedione, estrone, estrone sulfate, estradiol and SHBG as part of a case-control study nested within the cohort (497 cases and 1,384 controls. In year 2 of the project, we completed laboratory and statistical analyses of the association between breast cancer and the presence of the variant LH. This study was limited to subjects diagnosed at or after age 50. Laboratory analyses of subjects who were younger then age 50 at diagnoses have been completed and statistical analyses are underway.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1999
- Accession Number
- ADB258553
Entities
People
- Paolo G. Toniolo
Organizations
- NYU Langone Health